FDA inspection
Novartis Singapore Pharmaceutical Manufacturing Pte.: FDA inspection ending Nov 27, 2025
FDA inspection 1335754 · Voluntary Action Indicated (VAI) · Singapore
Key facts
| Inspection ID | 1335754 |
|---|---|
| Firm | Novartis Singapore Pharmaceutical Manufacturing Pte. |
| FEI number | 3012958979 |
| City | Singapore |
| Country | Singapore |
| Fiscal year | 2026 |
| Inspection end date | Nov 27, 2025 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data